Phase II Trial of Biweekly Infusional Fluorouracil, Folinic Acid, and Oxaliplatin in Patients With Advanced Gastric Cancer

2004184 citationsJournal Articlebronze Open Access

Authors

Salah‐Eddin Al‐Batran · Klinikum Darmstadt

Akin Atmaca · Krankenhaus Nordwest

Susanna Hegewisch‐Becker · Krankenhaus Nordwest

Dirk Jaeger · Krankenhaus Nordwest

S. Hahnfeld · University Medical Center Hamburg-Eppendorf

Mathias Rummel · Krankenhaus Nordwest

G. Seipelt ·

Abstract

Biweekly fluorouracil, folinic acid, and oxaliplatin is active and well-tolerated in patients with advanced gastric cancer. Response rates, time to progression, and overall survival were comparable to those achieved with other combination chemotherapy regimens, including FOLFOX6, with significantly less toxicity.

Topics & Keywords

Gastric Cancer Management and Outcomes Colorectal Cancer Treatments and Studies Gastrointestinal Tumor Research and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 22, Issue 4, pp. 658-663

DOI: 10.1200/jco.2004.07.042

Field-Weighted Citation Impact: 16.71